JPMorgan analyst Chris Schott reiterated an Overweight rating and $23.00 price target on Teva Pharma (NYSE: TEVA).The analyst comments "Ahead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE